Inventiva (IVA) announced the receipt of a $10M milestone payment from Chia Tai-Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharm. This milestone payment follows the successful settlement of the second tranche of EUR 115.6M in gross proceeds of the previously announced structured financing of up to EUR 348M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- 3 Best Stocks to Buy Now, 6/6/2025, According to Top Analysts
- Inventiva’s Lanifibranor: A Promising Investment in the MASH Space with Strong Phase III Progress and Financial Backing
- Inventiva Reports Q1 2025 Financials and Strategic Developments
- Inventiva’s Shareholders Approve Key Resolutions at May 2025 Meeting
- Inventiva Launches Share Repurchase Program to Boost Market Liquidity